Objectives: D-Cycloserine is an important second-line drug used to treat MDR-and XDR-TB. However, the mechanisms of resistance to D-cycloserine are not well understood. Here we investigated the molecular basis of D-cycloserine resistance using in vitro-isolated resistant mutants.
Introduction
D-Cycloserine is a cyclic analogue of D-alanine and is a broadspectrum antibiotic that inhibits the growth of Gram-positive and Gram-negative bacteria. Although D-cycloserine can elicit adverse psychiatric and nervous system reactions, it displays no cross-resistance with any other known antitubercular drugs. 1 D-Cycloserine is an important second-line drug for the treatment of MDR-and XDR-TB, 1 and is currently classified as a Group C agent for the treatment of MDR-TB by WHO (http://www.who.int/tb/ areas-of-work/drug-resistant-tb/treatment/resources/en/).
Since D-cycloserine is a structural analogue of D-alanine, enzymes with substrates of D-alanine are the drug targets of D-cycloserine in mycobacteria. [2] [3] [4] These enzymes include D-alanine racemase (Alr) and D-alanine:D-alanine ligase (Ddl), which are required for the synthesis of peptidoglycan in the mycobacterial cell wall. Overexpression of alr and ddl has been shown to cause resistance to D-cycloserine in Mycobacterium smegmatis. 5, 6 Moreover, SNPs in these genes were also found in resistant Mycobacterium tuberculosis. [7] [8] [9] Consistent with the cell-wall peptidoglycan being a target of D-cycloserine, previous studies have shown that D-cycloserine competitively inhibits both Alr and Ddl. 5, 10 However, a more recent metabolomic study showed that Ddl is a primary target of D-cycloserine and is preferentially inhibited over Alr in M. tuberculosis. 11 In addition, CycA is a transporter protein of D-alanine, D-serine and glycine, 12 and its SNP may partially contribute to the natural resistance to D-cycloserine in Mycobacterium bovis bacillus Calmette-Guérin (BCG). 9, 13 ald (Rv2780), encoding L-alanine dehydrogenase, was the fourth gene in M. tuberculosis, and its mutation was found in D-cycloserine-resistant clinical isolates. 9 However, mutations in cycA and ald only contribute to very low-level resistance and the ddl mutation was rarely found in studies without known phenotype in MDR/XDR-TB strains. 9 Despite the above progress, and significant advancements in general about the molecular understanding of drug resistance mechanisms in M. tuberculosis, 14 the distribution and characterization of D-cycloserine resistance in clinical strains are still unclear. This is partly due to the technical difficulties with D-cycloserine susceptibility testing such that routine phenotypic testing is not performed in clinical laboratories, 15, 16 as well as the poor understanding of the molecular basis of resistance to this drug. To better understand the mechanisms of D-cycloserine resistance and to develop more rapid molecular tests for detection of its resistance, we characterized 18 D-cycloserine-resistant mutants isolated in vitro from M. tuberculosis H37Rv and discovered a panel of new mutations associated with D-cycloserine resistance that have not previously been reported. 
Materials and methods

WGS analysis
Genomic DNA from 18 D-cycloserine-resistant mutants, as well as the parent strain M. tuberculosis H37Rv, was sequenced using MiSeq (Illumina, Inc.) as described previously, 17 except that paired-end sequencing libraries were constructed using Nextera XT DNA Sample Preparation kits (Illumina, Inc.) following manufacturer's instruction. For each isolate, 500 M to 1.5 G base (110-fold to 350-fold genome coverage) sequences were generated after barcodes were trimmed. Single-nucleotide variants (SNVs) and insertions and deletions (InDels) ranging from 1 to 5 bp were sorted and called with more than 4 reads using M. tuberculosis H37Rv genome (NC_018143.1) as a reference. Mutations in proline-glutamic acid (PE)/proline-proline-glutamic acid (PPE) family genes and regions having repetition sequences were excluded from the analysis. Mutations in the parent strain M. tuberculosis H37Rv compared with the genome online (NC_018143.1) were also excluded from the analysis.
PCR and DNA sequencing
The genomic DNA from D-cycloserine-resistant mutants isolated in vitro was then subjected to PCR amplification using primers described in Table 1 . The PCR products were obtained using the amplification parameters and sequenced by the Sanger method to confirm the mutations in these genes in selected mutants. 
Results and discussion
Mutations identified in D-cycloserine-resistant mutants by WGS
WGS of the 18 D-cycloserine-resistant mutants showed that 16 isolates had only one mutation (SNV or InDels) and 2 isolates had two mutations. In total, 16 different gene mutations were identified in the 18 mutants (Table 2) and it is of interest to note that none of these mutations was dominant. Non-synonymous mutations in 
Rv3772-For TGAGCTACGGGCGCTTGTCTTCAGTTG Rv3772-Rev Novel mutations associated with cycloserine resistance JAC alr (rv3423c), rv0059, betP (rv0917), rv0221, rv1403c, rv1683, rv1726, gabD2 (rv1731), rv2749, sugI (rv3331) and hisC2 (rv3772), a single mutation in the 5 0 intergenic region of rv3345c and rv1435c, and an insertion in the 3 0 region of rv0759c were identified as solo mutations in their respective cycloserine-resistant mutants, suggesting these mutations associated with cycloserine resistance are highly diverse. In addition, one mutant (DT61-1) had two mutations in alr (rv3423c), as well as a #52 G!T change in rv3345c (hypothetical protein), while the other mutant (DT3-2) had double mutations in both rv2831 and rv3690 (Table 2 ). Ten mutated genes (rv3690, rv0739c, rv1403c, rv1435c, rv2831, rv1726, rv1731, rv3331, rv3772 and alr) were verified by the Sanger sequencing method using primers and PCR conditions as described in Table 1 .
The two mutants DT61-1 and DT69-1 that had higher resistance to D-cycloserine (40 mg/L) had the same non-synonymous mutation in the alr gene (nucleotide change C1030T, causing amino acid change D344N). Except for alr, which is known to be involved in D-cycloserine resistance, 5, 6 the remaining 15 are novel and have not been reported previously. These 15 mutations include three lipid metabolism proteins (Rv0221, Rv1683, Rv2831), two transport proteins (BetP, SugI), one toxin/antitoxin (Rv0059), three proteins involved in intermediary metabolism and respiration (Rv1726, GabD2, HisC2), one methyltransferase (Rv1403c), one PE family protein (PE_PGRS50) and four unknown hypothetical proteins (Rv0759c, Rv1435c, Rv2749 and Rv3690). rv0059 is the toxin of a toxin/antitoxin module (Rv0059 and Rv0060). 18 One mutant (DT21-5) had an N-terminal stop codon mutation in the sugI gene, which resulted in complete loss of its protein function ( Table 2 ). The sugI gene encodes a probable sugar-transport integral membrane protein in M. tuberculosis. 19 Since the cycloserine structure is similar to natural furanose and the sugI mutation is the only mutation detected in the genome, D-cycloserine could use SugI as the transporter for intake into the cell. The loss-offunction mutation in sugI could result in a lower uptake of cycloserine inside the cell, therefore leading to higher resistance to Dcycloserine. This is consistent with the previous observation that a transport protein involved in alanine and serine uptake was implicated in the uptake and resistance of D-cycloserine. 4 BetP was the other transport protein whose SNV was detected in a different mutant DT71-1. BetP transports molecules with a quaternary ammonium group such as betaine, carnitine and choline. Whether mutations in SugI and BetP could cause resistance through altering the transport of D-cycloserine remains a matter of investigation for future studies.
Previous studies have attempted to identify the molecular basis of D-cycloserine resistance based on the analysis of only a few isolated D-cycloserine-resistant mutants. 4, 13 This study analysed the largest number of D-cycloserine-resistant mutants so far. It is worth noting that among the known D-cycloserine resistance-associated genes, we found mutations in alr in only 2 of 18 D-cycloserineresistant mutants (11%), but in none of the other known D-cycloserine resistance-associated genes (ddl, cycA or ald). Chen et al.
Instead, we found mutations in 16 novel genes that are associated with D-cycloserine resistance. Our finding of alr mutation in D-cycloserine-resistant mutants is consistent with a previous study that demonstrated Alr to be the primary target of D-cycloserine, 7 but is in contrast to a recent study suggesting that Ddl is a target of D-cycloserine. 11, 20 However, this could be a reflection of the relatively small number of strains (18 mutants) being analysed. Future investigations on more strains are required to better determine the frequency of the mutations in alr and ddl, as well as the new genes we identified in this work in D-cycloserine-resistant clinical strains. In addition, the role of the 16 novel genes in D-cycloserine resistance should be addressed in the future by molecular studies, such as overexpression studies, as well as by point mutation constructions and biochemical studies.
Although identification of mutations associated with resistance is generally useful for rapid molecular detection of drug resistance, the finding of diverse genes and mutations without significant clustering or conservation of resistance mechanisms associated with D-cycloserine resistance indicate it would be a challenge to develop a rapid molecular test to identify D-cycloserine resistance based on detection of mutations in candidate genes. This may partly explain why there are hardly any studies that find a good correlation between D-cycloserine resistance in MDR/XDR-TB strains and mutations in the genes alr and ddl known to be involved in D-cycloserine resistance. Future studies are needed to determine if D-cycloserine-resistant MDR/XDR-TB strains harbour any of the mutations associated with D-cycloserine resistance identified in this study. It is worth noting that the D-cycloserineresistant mutants we identified in this study are of low-level resistance (MIC " 20-40 mg/L), given the MIC for the parent strain H37Rv is about 10-20 mg/L. The clinical relevance of the low-level D-cycloserine resistance is unclear as the achievable serum concentration of D-cycloserine in patients is 20-35 mg/L. This will raise issues about a suitable cut-off for resistance. Additional MIC testing may be necessary in clinical strains to determine an adequate epidemiological cut-off (ECOFF) that separates susceptible and resistant populations or microbiological breakpoints, and an adequate resistant population cut-off (RCOFF) that correlates with clinical breakpoints and outcome. Future studies are needed to address the clinical significance of the low-level resistant strains in animals and humans and to establish an appropriate cut-off for resistance.
Conclusions
In conclusion, we identified novel mutations associated with D-cycloserine resistance in M. tuberculosis. Our findings indicate that the mechanisms of D-cycloserine resistance are quite complex in M. tuberculosis and involve genes participating in different cellular functions, such as lipid metabolism, methyltransferase, the stress response and transport systems. This study provides useful information for improved understanding of the molecular basis of D-cycloserine resistance and mechanisms of action and for molecular detection of D-cycloserine resistance for improved treatment of MDR-TB. Future studies are needed to validate our findings in clinical isolates with D-cycloserine resistance and to address the role of the newly identified mutations in causing D-cycloserine resistance in M. tuberculosis. 
